Transgenic T-Cell Receptor Adoptive Cell Therapies: Addressing Epigenetic Suppression & Optimizing Therapies with Immunosequencing

In this webinar, you will discover:

  • the principles of Adaptive Biotechnologies’ immunoSEQ® Assay and how its quantitative and scalable nature makes it uniquely suited to answer questions related to immuno-oncology
  • how clone tracking, repertoire properties, and T-cell fraction have been used to better understand T-cell therapy research in oncology
  • how the immunoSEQ Assay was utilized to better understand adoptive cell therapy response dynamics and inform future immunotherapy development

Immunosequencing, the science of profiling T- and B-cell receptors, has been widely used to understand how the adaptive immune system changes in various disease states and how different treatment modalities impact immune responses. In this webinar, Dr. Nate Polaske will provide a brief overview of immunosequencing with Adaptive Biotechnologies’ immunoSEQ® Technology. Dr. Scott Nowicki will then discuss his recent Cancer Discovery (1) publication that utilized the immunoSEQ Assay to explore epigenetic suppression during transgenic T-cell receptor adoptive cell therapy in melanoma and sarcoma patients.

1. Nowicki, TS et al. Epigenetic Suppression of Transgenic T-cell Receptor Expression via Gamma-Retroviral Vector Methylation in Adoptive Cell Transfer Therapy. Cancer Discov. 2020 Nov;10(11):1645-1653. doi: 10.1158/2159-8290.CD-20-0300.

For Research Use Only. Not for use in diagnostic procedures.


Theodore Scott Nowicki, MD, PhD

Division of Pediatric Hematology/Oncology

Nathan Polaske, PhD

Scientific Liaison,
Adaptive Biotechnologies

Register for SEQdiscovery

To access this webinar and all SEQdiscovery content.
If you have previously registered and opted to have an account please log in above.